A Pre‐Treatment Mass Spectrometry‐Based Serum Proteomic Test is Able to Stratify Patients with Ovarian Cancer Receiving Adjuvant Chemotherapy According to Overall and Disease‐Free Survival and Identify Patients Likely to Exhibit Chemo‐Resistance